Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human SNRPE Antibodies:
anti-Mouse (Murine) SNRPE Antibodies:
Go to our pre-filtered search.
Human Polyclonal SNRPE Primary Antibody for IHC, IHC (p) - ABIN4282574
Beltran-Sastre, Benisty, Burnier, Berger, Serrano, Kiel: Tuneable endogenous mammalian target complementation via multiplexed plasmid-based recombineering. in Scientific reports 2015
results confirm that BRAF V600E-positive hairy cell leukemia is a relatively rare disorder in the Japanese leukemia patient population.
BRAF (show BRAF Antibodies) and EGFR (show EGFR Antibodies) inhibitors are able to synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF (show BRAF Antibodies)(V600E)-mutant colorectal cancer cells
A diligent morphological examination to look for the presence of hairy cells along with flow cytometric immunophenotyping showing consistent bright expression of CD200 (show CD200 Antibodies), in addition to well-described characteristic immunophenotype, helps in correctly diagnosing the case. This can be further confirmed by the consistent presence of V600E point mutation in BRAF (show BRAF Antibodies) gene.
BRAF (show BRAF Antibodies) mutations are associated with colorectal liver metastases.
Multivariate analyses revealed that the PIK3CA (show PIK3CA Antibodies) mutation and clinical T stage were independent favorable prognostic factors (hazard ratio 0.34, 95% confidence interval: 0.12-0.96, p = 0.042). PIK3CA (show PIK3CA Antibodies) mutations were significantly associated with APC (show APC Antibodies) alterations (p = 0.0007) and BRAF (show BRAF Antibodies) mutations (p = 0.0090).
The present findings suggested that miR9 may suppress the viability ofpapillary thyroid carcinoma (PTC (show F9 Antibodies)) cells and inhibit tumor growth through directly targeting the expression of BRAF (show BRAF Antibodies) in PTC (show F9 Antibodies).
MET inactivation in the context of the BRAF (show BRAF Antibodies)-activating mutation is driven through a negative feedback loop involving inactivation of PP2A (show PPP2R4 Antibodies) phosphatase, which in turn leads to phosphorylation on MET inhibitory Ser985.
Data show that glycogen synthase kinase 3 (GSK3) and proto-oncogene (show RAB1A Antibodies) proteins B-raf (BRAF (show BRAF Antibodies))/MAPK (show MAPK1 Antibodies) signaling converges to control microphthalmia-associated transcription factor MITF (MITF (show MITF Antibodies)) nuclear export.
these results indicated that STAT3 (show STAT3 Antibodies)-mediated downexpression of miR (show MLXIP Antibodies)-579-3p caused resistance to vemurafenib. Our findings suggest novel approaches to overcome resistance to vemurafenib by combining vemurafenib with STAT3 (show STAT3 Antibodies) sliencing or miR (show MLXIP Antibodies)-579-3p overexpression.
Despite the presence of histological findings indicating long-standing gastroesophageal reflux in 25%, as well as symptomatic gastroesophageal reflux in more than 40%, there was no detectable tissue expression of KRAS or BRAF (show BRAF Antibodies) mutations in adult patients treated for esophageal atresia in childhood.
mosaic expression of BRAF (show BRAF Antibodies)(V600E) in mouse erythro-myeloid progenitors results in clonal expansion of tissue-resident macrophages and a severe late-onset neurodegenerative disorder
CDX2 (show CDX2 Antibodies)(Null)/BRAF (show BRAF Antibodies)(V600E) expression in adult mouse intestinal epithelium led to serrated morphology tumors (including carcinomas) and BRAF (show BRAF Antibodies)(V600E) potently interacted with CDX2 (show CDX2 Antibodies) silencing to alter gene expression. Like human serrated lesions, CDX2 (show CDX2 Antibodies)(Null)/BRAF (show BRAF Antibodies)(V600E)-mutant epithelium expressed gastric markers.
expression of an endogenous Braf (show BRAF Antibodies)(D631A) kinase-inactive isoform in mice (corresponding to the human BRAF (show BRAF Antibodies)(D594A) mutation) triggers lung adenocarcinoma in vivo, indicating that BRAF (show BRAF Antibodies)-inactivating mutations are initiating events in lung oncogenesis
TTM (show SLITRK1 Antibodies) reduces copper levels and MAPK (show MAPK1 Antibodies) signaling, thereby inhibiting BRAF (show BRAF Antibodies)(V600E)-driven melanoma tumor growth.
BRAF (show BRAF Antibodies) and ROKalpha (show ROCK2 Antibodies) form independent RAF1 (show RAF1 Antibodies) complexes in embryonic fibroblasts (MEFs) treated with epidermal growth factor (EGF (show EGF Antibodies)).
Braf (show BRAF Antibodies)(V600E) expression, coupled with simultaneous p53 (show TP53 Antibodies) ablation, permits bypass of senescence and progression to lung adenocarcinoma.
These results provide support for the role of BRAF (show BRAF Antibodies)(V600E) in metastasis.
Mechanistically, BRAF (show BRAF Antibodies) and RAF1 (show RAF1 Antibodies) operate independently to balance MAPK (show MAPK1 Antibodies) signaling: BRAF (show BRAF Antibodies) promotes ERK (show EPHB2 Antibodies) activation, while RAF1 (show RAF1 Antibodies) dims stress kinase activation.
Mass spectrometry based screening for potential interaction partners revealed that BRAF (show BRAF Antibodies) interacts and phosphorylates PAX3 (show PAX3 Antibodies).
Using a conditional allele for Braf (show BRAF Antibodies)(V600E) , a mutation observed in clinical cases of GIST, authors observed that Braf (show BRAF Antibodies)(V600E) activation was sufficient to drive ICC hyperplasia but not GIST tumorigenesis.
This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene.
94 kDa B-raf protein
, B-Raf proto-oncogene serine/threonine-protein kinase (p94)
, murine sarcoma viral (v-raf) oncogene homolog B1
, proto-oncogene B-Raf
, serine/threonine-protein kinase B-raf
, v-raf murine sarcoma viral oncogene homolog B1
, sm protein E
, small nuclear ribonucleoprotein E
, small nuclear ribonucleoprotein polypeptide E
, SmE protein